K. N.

615 total citations
21 papers, 509 citations indexed

About

K. N. is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, K. N. has authored 21 papers receiving a total of 509 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in K. N.'s work include Prostate Cancer Treatment and Research (11 papers), Prostate Cancer Diagnosis and Treatment (4 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). K. N. is often cited by papers focused on Prostate Cancer Treatment and Research (11 papers), Prostate Cancer Diagnosis and Treatment (4 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). K. N. collaborates with scholars based in Canada, United States and Switzerland. K. N.'s co-authors include Martin Gleave, Hideaki Miyake, Anthony W. Tolcher, Nicholas Murray, C. Bryce, Susan D’Aloisio, Richard Klasa, Christian Kollmannsberger, Jean Powers and Holger W. Hirte and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology and Investigational New Drugs.

In The Last Decade

K. N.

21 papers receiving 503 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. N. Canada 11 286 213 208 144 52 21 509
Victoria Rimkunas United States 10 276 1.0× 225 1.1× 272 1.3× 108 0.8× 35 0.7× 26 556
Rana Sullivan United States 10 349 1.2× 323 1.5× 259 1.2× 86 0.6× 53 1.0× 19 643
Sonal J. Desai United States 8 186 0.7× 210 1.0× 155 0.7× 95 0.7× 49 0.9× 10 424
Anuradha Waghray United States 8 233 0.8× 191 0.9× 97 0.5× 123 0.9× 27 0.5× 10 491
Guoping Ren China 15 250 0.9× 314 1.5× 181 0.9× 217 1.5× 54 1.0× 40 654
Evangelos Bournakis Greece 15 272 1.0× 160 0.8× 267 1.3× 153 1.1× 39 0.8× 35 621
Caterina Aversa Italy 12 210 0.7× 222 1.0× 285 1.4× 108 0.8× 62 1.2× 32 553
S. Kim United States 7 300 1.0× 176 0.8× 128 0.6× 87 0.6× 91 1.8× 12 436
F. Fritzsche Germany 9 537 1.9× 163 0.8× 219 1.1× 134 0.9× 28 0.5× 14 788

Countries citing papers authored by K. N.

Since Specialization
Citations

This map shows the geographic impact of K. N.'s research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. N. with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. N. more than expected).

Fields of papers citing papers by K. N.

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. N.. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. N.. The network helps show where K. N. may publish in the future.

Co-authorship network of co-authors of K. N.

This figure shows the co-authorship network connecting the top 25 collaborators of K. N.. A scholar is included among the top collaborators of K. N. based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. N.. K. N. is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tsang, Erica S., Connor M. Forbes, K. N., Bernhard J. Eigl, & Sunil Parimi. (2019). Second-Line Systemic Therapies for Metastatic Urothelial Carcinoma: A Population-Based Cohort Analysis. Current Oncology. 26(2). 260–265. 3 indexed citations
2.
Eigl, Bernhard J., Scott North, Eric Winquist, et al.. (2015). A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Investigational New Drugs. 33(4). 969–976. 54 indexed citations
3.
N., K., Anthony W. Tolcher, Peter P. Lee, et al.. (2012). Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 71(1). 237–244. 28 indexed citations
4.
Tolcher, Anthony W., K. N., Neal D. Shore, et al.. (2012). Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 70(2). 305–313. 27 indexed citations
5.
6.
Eigl, Bernhard J., Marc Trudeau, Eric Winquist, et al.. (2011). A phase II study of sunitinib (SU) for maintenance therapy in metastatic castration-resistant prostate cancer (mCRPC) after response to docetaxel (D).. Journal of Clinical Oncology. 29(7_suppl). 151–151. 3 indexed citations
7.
Hotte, Sébastien J., et al.. (2010). Phase I trial of OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results.. Journal of Clinical Oncology. 28(15_suppl). 3077–3077. 15 indexed citations
8.
Hotte, Sébastien J., et al.. (2009). OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a first-in-human trial. Journal of Clinical Oncology. 27(15_suppl). 3506–3506. 13 indexed citations
9.
Rathkopf, Dana E., K. N., Ulka N. Vaishampayan, et al.. (2009). Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 27(15_suppl). 5064–5064. 6 indexed citations
10.
11.
Kollmannsberger, Christian, D.Y.C. Heng, Nevin Murray, & K. N.. (2007). A population-based study evaluating metastatic renal cell cancer (mRCC) patients treated with interferon (IFN) alone, first-line IFN then second-line sunitinib, or sunitinib alone. Journal of Clinical Oncology. 25(18_suppl). 15572–15572. 6 indexed citations
12.
McKenzie, Michael, K. N., A. J. Neville, et al.. (2006). Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP). Journal of Clinical Oncology. 24(18_suppl). 4631–4631. 2 indexed citations
13.
Hagey, A., Robert A. Figlin, Nancy P. Moldawer, et al.. (2005). Preliminary phase 2 results of ABT-751 in subjects with advanced renal cell carcinoma (RCC). Journal of Clinical Oncology. 23(16_suppl). 4603–4603. 5 indexed citations
14.
N., K., Lillian L. Siu, Holger W. Hirte, et al.. (2005). A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCIC CTG IND.154. Journal of Clinical Oncology. 23(16_suppl). 3085–3085. 12 indexed citations
15.
Michels, Jorg, et al.. (2005). First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer (HRPC): Does sequence matter?. Journal of Clinical Oncology. 23(16_suppl). 4611–4611. 14 indexed citations
16.
Gleave, M.E., K. N., Larry Goldenberg, et al.. (2004). Multicentre phase II trial of combination neoadjuvant hormone therapy and weekly docetaxel prior to radical prostatectomy in high risk localized prostate cancer (CUOG-P01a). Journal of Clinical Oncology. 22(14_suppl). 4635–4635. 3 indexed citations
17.
N., K., Ladan Fazli, Edward C. Jones, et al.. (2004). A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy. Journal of Clinical Oncology. 22(14_suppl). 3033–3033. 14 indexed citations
18.
Gleave, Martin, K. N., Larry Goldenberg, et al.. (2004). Multicentre phase II trial of combination neoadjuvant hormone therapy and weekly docetaxel prior to radical prostatectomy in high risk localized prostate cancer (CUOG-P01a). Journal of Clinical Oncology. 22(14_suppl). 4635–4635. 3 indexed citations
19.
N., K., Martin Gleave, Richard Klasa, et al.. (2001). A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.. PubMed. 7(12). 3920–7. 156 indexed citations
20.
Miyake, Hideaki, K. N., & Martin Gleave. (2000). Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.. PubMed. 6(5). 1655–63. 129 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Victoria Rimkunas Breakdown of academic impact, for papers by Rana Sullivan Breakdown of academic impact, for papers by Sonal J. Desai Breakdown of academic impact, for papers by Anuradha Waghray Breakdown of academic impact, for papers by Guoping Ren Breakdown of academic impact, for papers by Evangelos Bournakis Breakdown of academic impact, for papers by Caterina Aversa Breakdown of academic impact, for papers by S. Kim Breakdown of academic impact, for papers by F. Fritzsche
Rankless by CCL
2026